Last $48.85 USD
Change Today 0.00 / 0.00%
Volume 100.0
SHPGF On Other Exchanges
Symbol
Exchange
SHPGF is not on other exchanges.
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

shire plc (SHPGF) Snapshot

Open
$48.85
Previous Close
$48.85
Day High
$48.85
Day Low
$48.85
52 Week High
02/27/14 - $57.05
52 Week Low
05/7/13 - $28.50
Market Cap
28.8B
Average Volume 10 Days
531.9
EPS TTM
--
Shares Outstanding
588.9M
EX-Date
03/5/14
P/E TM
--
Dividend
$12.00
Dividend Yield
0.41%
Current Stock Chart for SHIRE PLC (SHPGF)

shire plc (SHPGF) Details

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; ELVANSE/TYVENSE; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, it offers FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. Further, the company provides REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. Additionally, it offers FOSRENOL for the treatment of hyperphosphatemia in end stage renal disease; XAGRID for the reduction of elevated platelet counts; and CINRYZE, a C1 esterase inhibitor therapy for routine prophylaxis against hereditary angioedema. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. Shire plc markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. The company sells its products in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc has research collaboration with Santaris Pharma A/S. The company was founded in 1986 and is headquartered in Dublin, Ireland.

5,338 Employees
Last Reported Date: 02/24/14
Founded in 1986

shire plc (SHPGF) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $2.7M
Compensation as of Fiscal Year 2013.

shire plc (SHPGF) Key Developments

Shire Pharmaceuticals Announces the Voluntary Recall in the United States of VPRIV

Shire Pharmaceuticals announced the initiation of a voluntary recall in the United States of one batch, packaged into three lots, of VPRIV due to the presence of visible particulate matter, identified as stainless steel and barium sulfate. The particulate matter was found in a small number of vials in the three packaged lots of VPRIV. A Shire investigation identified the particulate matter root cause as the third party supplier fill finish process. Shire believes the safety risk to patients is very low. If infused, there is a possibility of rare but serious adverse events associated with particulate containing barium sulfate. Shire believes this health risk was and continues to be mitigated by the package insert's required visual inspection of the reconstituted VPRIV product and by administration of VPRIV through an in-line low protein-binding filter. The product is being recalled and should not be used. Importantly, there have been no reported adverse events or customer complaints associated with the use of these lots. To ensure that patients are not exposed to foreign particles during administration, Shire is reinforcing recommendations of the approved package insert in order to mitigate any risk: (1) visual inspection of the reconstituted VPRIV product should be done prior to administration and (2) VPRIV should be administered through an in-line low protein-binding filter. The safety profile of VPRIV remains unchanged. VPRIV is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for pediatric and adult patients with type 1 Gaucher disease. VPRIV is supplied as a sterile, preservative-free, lyophilized powder in single-use vials, for intravenous use. This voluntary recall is limited to the following packaged lots: FEW13-001, FEW13-002, and FED13-006. These lots were distributed nationwide to hospitals, infusion clinics, patients, and home health agencies in the United States and all have the same NDC code (54092-701-04) and same expiration date of 10/15 (Oct 2015). Shire has notified patients, hospitals, infusion clinics, and home health agencies via letter not to use product from the recalled lots. Customers should locate and remove all affected product from their facility and/or residence. Shire has significant quantities of VPRIV to replace any affected product. Shire does not anticipate any disruption in supply as a result of this voluntary recall. Unaffected lots of VPRIV can continue to be used according to the instructions for use. This voluntary recall is being conducted with the knowledge of the U.S. Food and Drug Administration. Important safety information for VPRIV: The most serious side effects seen in patients in clinical trials with VPRIV were hypersensitivity reactions, including one case of anaphylaxis. Hypersensitivity reactions in the clinical trials include any event considered related to and occurring within 24 hours of VPRIV infusion. The most common side effects seen in patients in clinical trials with VPRIV were hypersensitivity reactions. Patients were not routinely pre-medicated prior to infusion of VPRIV. The most commonly observed symptoms of hypersensitivity reactions include headache, dizziness, low blood pressure, high blood pressure, nausea, weakness/fatigue, and fever. Generally, the reactions were mild and, in newly treated patients, occurred mostly during the first 6 months of treatment and tended to occur less frequently with time. Management of hypersensitivity reactions should be based on severity of the reactions and may include slowing the infusion rate, treatment with medications such as antihistamines, fever-reducing agents and/or corticosteroids, and/or stopping and resuming treatment with increased infusion time. The most commonly reported side effects (occurring in >= 10% of patients) that were considered related to VPRIV included: hypersensitivity reactions, headache, dizziness, abdominal pain, nausea, back pain, joint pain, upper respiratory tract infection, aPTT prolonged (eg, blood clotting difficulty), fever and weakness/fatigue. All adult side effects of VPRIV are considered relevant to children (ages 4 to 17 years). Side effects more commonly seen in children compared with adult patients included: upper respiratory tract infection, rash, aPTT prolonged, and fever. The safety of VPRIV has not been established in patients younger than 4 years of age. As with all therapeutic proteins, there is a potential of developing antibodies. It is unknown if the presence of antibodies to VPRIV is associated with a higher risk of infusion reactions. Patients with an immune response to other enzyme replacement therapies who are switching to VPRIV should continue to be monitored for antibodies.

Shire plc Presents at Boston Biotech BD Boston Conference, Mar-25-2014 through Mar-26-2014

Shire plc Presents at Boston Biotech BD Boston Conference, Mar-25-2014 through Mar-26-2014. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Presentation Date & Speakers: Mar-25-2014, Jeff Poulton, Sam Rasty.

Shire Pharmaceuticals Presents at 8th Annual BIO Europe Spring 2014, Mar-10-2014 04:00 PM

Shire Pharmaceuticals Presents at 8th Annual BIO Europe Spring 2014, Mar-10-2014 04:00 PM. Venue: OVAL Lingotto, Turin, Italy. Speakers: Naina Bhasin, Director, Scientific Licensing, Business Development.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SHPGF:US $48.85 USD 0.00

SHPGF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan Inc/United States $133.92 USD +2.46
CSL Ltd A$67.68 AUD +0.15
Forest Laboratories Inc $89.58 USD -0.71
UCB SA €57.82 EUR -0.18
Valeant Pharmaceuticals International Inc C$134.45 CAD +0.80
View Industry Companies
 

Industry Analysis

SHPGF

Industry Average

Valuation SHPGF Industry Range
Price/Earnings 20.3x
Price/Sales 5.5x
Price/Book 5.1x
Price/Cash Flow 43.1x
TEV/Sales 5.8x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC, please visit www.shire.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.